Diabetes drug could help kidney dialysis patients
NCT ID NCT06913647
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether canagliflozin, a diabetes drug, can improve fluid removal and reduce scarring in people on peritoneal dialysis for kidney failure. Thirty adults will receive either the drug or a placebo for 26 weeks, then switch. The goal is to see if the drug helps the dialysis membrane work better and stay healthier.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Canagliflozin (Invokana) 300 mg tablet
What this could lead to
If it works, this could point toward a way to make peritoneal dialysis more effective and slow damage to the lining of the belly.
What could go wrong
This is a small, early-phase proof-of-concept trial with only 30 participants. The drug may not improve dialysis outcomes or could cause side effects like ketoacidosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Institute-McGill University Health Center
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••